Risk of thromboembolism in patients with ALK- and EGFR-mutant lung cancer: A cohort study

Patients with ALK-mutant advanced lung adenocarcinoma have the highest rate of TE. TE is associated with worse survival across molecular subtypes. These findings should be taken into consideration in decision-making regarding thromboprophylaxis. READ ARTICLE

Journal of Thrombosis and Haemostasis DOI:doi.org/10.1111/jth.15215

Authors: Joanna Roopkumar,Shyam K. Poudel,Lorenzo Gervaso,Chandana A. Reddy,Vamsidhar Velcheti,Nathan A. Pennell,Keith R. McCrae,Alok A. Khorana

Real-World OutcomesKirk SmithDecember 14, 2020anaplastic lymphocyte kinase (ALK), epidermal growth factor receptor (EGFR), molecular subtyping, non-small cell lung cancer (NSCLC), thromboembolism

Risk of thromboembolism in patients with ALK‐ and EGFR‐mutant lung cancer: A cohort study

Patients with ALK‐mutant advanced lung adenocarcinoma have the highest rate of TE. TE is associated with worse survival across molecular subtypes. These findings should be taken into consideration in decision‐making regarding thromboprophylaxis. READ ARTICLE

Journal of Thrombosis Haemostasis DOI: 10.1111/jth.15215

Authors: Roopkumar J., Poudel S.K., Gervaso L., Reddy C.A., Velcheti V., Pennell N.A., McCrae K.R., Khorana A.A.

Case StudyKirk SmithNovember 30, 2020ALK, EGFR, molecular subtyping, NSCLC, thromboembolism